FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090608460> ?p ?o ?g. }

• W2090608460 endingPage "559" @default.
• W2090608460 startingPage "554" @default.
• W2090608460 abstract "Momordica charantia, locally known as Ampalaya, is being widely used and advertised for its hypoglycemic effects. However, to date, no large clinical trial has been published on the efficacy of any type of preparation. The main objective of this study is to determine if addition of M. charantia capsules to standard therapy can decrease glycosylated hemoglobin (hemoglobin A1c or HbA1c) levels in diabetic patients with poor sugar control.A randomized, double-blind, placebo-controlled trial was conducted between April and September 2004 at the outpatient clinics of the Philippine General Hospital. The trial included 40 patients, 18 years old and above, who were either newly diagnosed or poorly controlled type 2 diabetics with A1c levels between 7% and 9%. On top of the standard therapy, the patients were randomized to either M. charantia capsules or placebo. The treatment group received two capsules of M. charantia three times a day after meals, for 3 months. The control group received placebo at the same dose. The primary efficacy endpoint was change in the A1c level in the two groups. The secondary efficacy endpoints included its effect on fasting blood sugar, serum cholesterol, and weight. Safety endpoints included effects on serum creatinine, hepatic transaminases (Alanine aminotransferase/ALT and Aspartate aminotransferase/AST), sodium, potassium, and adverse events.Baseline characteristics between the treatment and control groups were similar. The difference in mean change in A1c between the two groups was 0.22% in favor of M. charantia (95% CI: -0.40 to 0.84) with P=0.4825. There was no significant effect on mean fasting blood sugar, total cholesterol, and weight or on serum creatinine, ALT, AST, sodium, and potassium. There were few adverse events and these were generally mild.This is the first randomized controlled trial to shed light on the issue concerning the hypoglycemic effects of M. charantia. The investigators targeted a 1% decline in A1c at the outset with an estimated power of 88%. With the observed decline of 0.24%, the achieved power was only 11%. For this reason, we are unable to make a definite conclusion about the effectiveness of M. charantia. However, the results of this study can be used estimate the sample size for bigger studies." @default.
• W2090608460 created "2016-06-24" @default.
• W2090608460 creator A5023804246 @default.
• W2090608460 creator A5023897864 @default.
• W2090608460 creator A5031193818 @default.
• W2090608460 creator A5059379004 @default.
• W2090608460 creator A5074922044 @default.
• W2090608460 creator A5082660847 @default.
• W2090608460 creator A5087691049 @default.
• W2090608460 date "2007-06-01" @default.
• W2090608460 modified "2023-10-01" @default.
• W2090608460 title "The effect of Momordica charantia capsule preparation on glycemic control in Type 2 Diabetes Mellitus needs further studies" @default.
• W2090608460 cites W1931911624 @default.
• W2090608460 cites W1963644695 @default.
• W2090608460 cites W1979808880 @default.
• W2090608460 cites W1986782309 @default.
• W2090608460 cites W1997695869 @default.
• W2090608460 cites W2007817096 @default.
• W2090608460 cites W2068373977 @default.
• W2090608460 cites W2080860314 @default.
• W2090608460 cites W2091603419 @default.
• W2090608460 cites W2092429715 @default.
• W2090608460 cites W2109221964 @default.
• W2090608460 cites W2139600422 @default.
• W2090608460 cites W2142575878 @default.
• W2090608460 doi "https://doi.org/10.1016/j.jclinepi.2006.07.009" @default.
• W2090608460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17493509" @default.
• W2090608460 hasPublicationYear "2007" @default.
• W2090608460 type Work @default.
• W2090608460 sameAs 2090608460 @default.
• W2090608460 citedByCount "155" @default.
• W2090608460 countsByYear W20906084602012 @default.
• W2090608460 countsByYear W20906084602013 @default.
• W2090608460 countsByYear W20906084602014 @default.
• W2090608460 countsByYear W20906084602015 @default.
• W2090608460 countsByYear W20906084602016 @default.
• W2090608460 countsByYear W20906084602017 @default.
• W2090608460 countsByYear W20906084602018 @default.
• W2090608460 countsByYear W20906084602019 @default.
• W2090608460 countsByYear W20906084602020 @default.
• W2090608460 countsByYear W20906084602021 @default.
• W2090608460 countsByYear W20906084602022 @default.
• W2090608460 countsByYear W20906084602023 @default.
• W2090608460 crossrefType "journal-article" @default.
• W2090608460 hasAuthorship W2090608460A5023804246 @default.
• W2090608460 hasAuthorship W2090608460A5023897864 @default.
• W2090608460 hasAuthorship W2090608460A5031193818 @default.
• W2090608460 hasAuthorship W2090608460A5059379004 @default.
• W2090608460 hasAuthorship W2090608460A5074922044 @default.
• W2090608460 hasAuthorship W2090608460A5082660847 @default.
• W2090608460 hasAuthorship W2090608460A5087691049 @default.
• W2090608460 hasConcept C126322002 @default.
• W2090608460 hasConcept C134018914 @default.
• W2090608460 hasConcept C141071460 @default.
• W2090608460 hasConcept C142724271 @default.
• W2090608460 hasConcept C168563851 @default.
• W2090608460 hasConcept C197934379 @default.
• W2090608460 hasConcept C203092338 @default.
• W2090608460 hasConcept C204787440 @default.
• W2090608460 hasConcept C27081682 @default.
• W2090608460 hasConcept C2777180221 @default.
• W2090608460 hasConcept C2778686829 @default.
• W2090608460 hasConcept C2778917026 @default.
• W2090608460 hasConcept C2779306644 @default.
• W2090608460 hasConcept C2780306776 @default.
• W2090608460 hasConcept C2780473172 @default.
• W2090608460 hasConcept C2780485761 @default.
• W2090608460 hasConcept C2910068830 @default.
• W2090608460 hasConcept C535046627 @default.
• W2090608460 hasConcept C555293320 @default.
• W2090608460 hasConcept C556039675 @default.
• W2090608460 hasConcept C71924100 @default.
• W2090608460 hasConcept C90924648 @default.
• W2090608460 hasConceptScore W2090608460C126322002 @default.
• W2090608460 hasConceptScore W2090608460C134018914 @default.
• W2090608460 hasConceptScore W2090608460C141071460 @default.
• W2090608460 hasConceptScore W2090608460C142724271 @default.
• W2090608460 hasConceptScore W2090608460C168563851 @default.
• W2090608460 hasConceptScore W2090608460C197934379 @default.
• W2090608460 hasConceptScore W2090608460C203092338 @default.
• W2090608460 hasConceptScore W2090608460C204787440 @default.
• W2090608460 hasConceptScore W2090608460C27081682 @default.
• W2090608460 hasConceptScore W2090608460C2777180221 @default.
• W2090608460 hasConceptScore W2090608460C2778686829 @default.
• W2090608460 hasConceptScore W2090608460C2778917026 @default.
• W2090608460 hasConceptScore W2090608460C2779306644 @default.
• W2090608460 hasConceptScore W2090608460C2780306776 @default.
• W2090608460 hasConceptScore W2090608460C2780473172 @default.
• W2090608460 hasConceptScore W2090608460C2780485761 @default.
• W2090608460 hasConceptScore W2090608460C2910068830 @default.
• W2090608460 hasConceptScore W2090608460C535046627 @default.
• W2090608460 hasConceptScore W2090608460C555293320 @default.
• W2090608460 hasConceptScore W2090608460C556039675 @default.
• W2090608460 hasConceptScore W2090608460C71924100 @default.
• W2090608460 hasConceptScore W2090608460C90924648 @default.
• W2090608460 hasIssue "6" @default.
• W2090608460 hasLocation W20906084601 @default.
• W2090608460 hasLocation W20906084602 @default.

• next